Adaptive Biotechnologies Corp Insider Trading for September 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Adaptive Biotechnologies Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Adaptive Biotechnologies Corp for September 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 28 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 6.55 | 1,771 | 11,600 | 31,875 | |
| Sep 28 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 7.80 | 1,109 | 8,650 | 36,145 | |
| Sep 28 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 48.49 | 596 | 28,900 | 1,300 | 1.9 K to 1.3 K (-31.43 %) |
| Sep 28 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 47.59 | 2,284 | 108,696 | 1,896 | 4.2 K to 1.9 K (-54.64 %) |
| Sep 28 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 6.55 | 1,771 | 11,600 | 4,180 | 2.4 K to 4.2 K (+73.52 %) |
| Sep 28 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 7.80 | 1,109 | 8,650 | 2,409 | 1.3 K to 2.4 K (+85.31 %) |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 300,300 | |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 311,400 | |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 322,500 | |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 47.98 | 3,900 | 187,122 | 679 | 4.6 K to 679 (-85.17 %) |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 47.28 | 3,560 | 168,317 | 4,579 | 8.1 K to 4.6 K (-43.74 %) |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 46.00 | 3,640 | 167,440 | 8,139 | 11.8 K to 8.1 K (-30.90 %) |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 11,779 | 679 to 11.8 K (+1,634.76 %) |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 48.16 | 11,100 | 534,576 | 679 | 11.8 K to 679 (-94.24 %) |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 11,779 | 679 to 11.8 K (+1,634.76 %) |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 47.95 | 4,100 | 196,595 | 679 | 4.8 K to 679 (-85.79 %) |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 47.34 | 7,000 | 331,380 | 4,779 | 11.8 K to 4.8 K (-59.43 %) |
| Sep 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 11,779 | 679 to 11.8 K (+1,634.76 %) |
| Sep 23 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.27 | 417 | 2,615 | 2,917 | |
| Sep 23 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 45.51 | 417 | 18,978 | 0 | 417 to 0 (-100.00 %) |
| Sep 23 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.27 | 417 | 2,615 | 417 | 0 to 417 |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 194,640 | |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 211,320 | |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 228,000 | |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 46.13 | 8,580 | 395,795 | 1,778,180 | 1.8 M to 1.8 M (-0.48 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.28 | 8,100 | 366,768 | 1,786,760 | 1.8 M to 1.8 M (-0.45 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.26 | 14,080 | 637,261 | 1,778,180 | 1.8 M to 1.8 M (-0.79 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 44.48 | 2,600 | 115,648 | 1,792,260 | 1.8 M to 1.8 M (-0.14 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 194,640 | |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 48.26 | 400 | 19,304 | 1,778,180 | 1.8 M to 1.8 M (-0.02 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 211,320 | |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 47.46 | 5,100 | 242,046 | 1,778,580 | 1.8 M to 1.8 M (-0.29 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 228,000 | |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 46.45 | 5,000 | 232,250 | 1,738,680 | 1.7 M to 1.7 M (-0.29 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 46.13 | 8,580 | 395,795 | 1,778,180 | 1.8 M to 1.8 M (-0.48 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.47 | 6,180 | 281,005 | 1,788,680 | 1.8 M to 1.8 M (-0.34 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.28 | 8,100 | 366,768 | 1,786,760 | 1.8 M to 1.8 M (-0.45 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.26 | 14,080 | 637,261 | 1,778,180 | 1.8 M to 1.8 M (-0.79 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 44.48 | 2,600 | 115,648 | 1,792,260 | 1.8 M to 1.8 M (-0.14 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 48.26 | 400 | 19,304 | 1,778,180 | 1.8 M to 1.8 M (-0.02 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 47.46 | 5,100 | 242,046 | 1,778,580 | 1.8 M to 1.8 M (-0.29 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 46.45 | 5,000 | 232,250 | 1,738,680 | 1.7 M to 1.7 M (-0.29 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 45.47 | 6,180 | 281,005 | 1,788,680 | 1.8 M to 1.8 M (-0.34 %) |
| Sep 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 65,000 | |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 42.58 | 2,000 | 85,160 | 0 | 2 K to 0 (-100.00 %) |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 2,000 | 0 to 2 K |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Option Exercise | M | 7.80 | 2,000 | 15,600 | 192,000 | |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Sell | S | 42.58 | 2,000 | 85,160 | 0 | 2 K to 0 (-100.00 %) |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Buy | M | 7.80 | 2,000 | 15,600 | 2,000 | 0 to 2 K |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, External Affai ... | Option Exercise | M | 6.32 | 25,000 | 158,000 | 55,000 | |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, External Affai ... | Option Exercise | M | 6.55 | 25,000 | 163,750 | 205,000 | |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, External Affai ... | Sell | S | 44.00 | 25,000 | 1,100,000 | 0 | 25 K to 0 (-100.00 %) |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, External Affai ... | Buy | M | 6.32 | 25,000 | 158,000 | 25,000 | 0 to 25 K |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, External Affai ... | Sell | S | 42.50 | 25,000 | 1,062,500 | 0 | 25 K to 0 (-100.00 %) |
| Sep 16 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, External Affai ... | Buy | M | 6.55 | 25,000 | 163,750 | 25,000 | 0 to 25 K |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 8,588 | 54,276 | 580,000 | |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 1,412 | 8,924 | 588,588 | |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.00 | 8,588 | 343,520 | 1,000 | 9.6 K to 1,000 (-89.57 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 8,588 | 54,276 | 9,588 | 1,000 to 9.6 K (+858.80 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.00 | 1,412 | 56,480 | 1,000 | 2.4 K to 1,000 (-58.54 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 8,588 | 54,276 | 580,000 | |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 1,412 | 8,924 | 2,412 | 1,000 to 2.4 K (+141.20 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 1,412 | 8,924 | 588,588 | |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | M | 7.80 | 4,149 | 32,362 | 425,000 | |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.00 | 8,588 | 343,520 | 1,000 | 9.6 K to 1,000 (-89.57 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | M | 7.80 | 18 | 140 | 429,149 | |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 8,588 | 54,276 | 9,588 | 1,000 to 9.6 K (+858.80 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Sell | S | 40.00 | 4,149 | 165,960 | 0 | 4.1 K to 0 (-100.00 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.00 | 1,412 | 56,480 | 1,000 | 2.4 K to 1,000 (-58.54 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Buy | M | 7.80 | 4,149 | 32,362 | 4,149 | 0 to 4.1 K |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 1,412 | 8,924 | 2,412 | 1,000 to 2.4 K (+141.20 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Sell | S | 40.00 | 18 | 720 | 0 | 18 to 0 (-100.00 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Buy | M | 7.80 | 18 | 140 | 18 | 0 to 18 |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | M | 7.80 | 4,149 | 32,362 | 425,000 | |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | M | 7.80 | 18 | 140 | 429,149 | |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Sell | S | 40.00 | 4,149 | 165,960 | 0 | 4.1 K to 0 (-100.00 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Buy | M | 7.80 | 4,149 | 32,362 | 4,149 | 0 to 4.1 K |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Sell | S | 40.00 | 18 | 720 | 0 | 18 to 0 (-100.00 %) |
| Sep 11 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Buy | M | 7.80 | 18 | 140 | 18 | 0 to 18 |
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 20,000 | 126,400 | 590,000 | |
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 36.17 | 20,000 | 723,400 | 1,000 | 21 K to 1,000 (-95.24 %) |
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 20,000 | 126,400 | 21,000 | 1,000 to 21 K (+2,000.00 %) |
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | M | 7.80 | 2,083 | 16,247 | 429,167 | |
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Sell | S | 36.17 | 2,083 | 75,342 | 0 | 2.1 K to 0 (-100.00 %) |
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Buy | M | 7.80 | 2,083 | 16,247 | 2,083 | 0 to 2.1 K |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 7.27 | 1,563 | 11,363 | 43,750 | |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 2,604 | 17,056 | 65,105 | |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 2,604 | 17,056 | 36,459 | |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 41.75 | 300 | 12,525 | 0 | 300 to 0 (-100.00 %) |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 41.28 | 6,471 | 267,123 | 300 | 6.8 K to 300 (-95.57 %) |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 7.27 | 1,563 | 11,363 | 6,771 | 5.2 K to 6.8 K (+30.01 %) |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 2,604 | 17,056 | 5,208 | 2.6 K to 5.2 K (+100.00 %) |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 2,604 | 17,056 | 2,604 | 0 to 2.6 K |